Key result
Metabolic syndrome was associated with increased odds of chronic kidney disease in individuals with hypertension and/or diabetes (OR 2.07; 95% CI 1.25-3.44).
Why the study?
The study was conducted to identify the associations between metabolic syndrome and its components with chronic kidney disease in individuals with hypertension and/or diabetes mellitus in primary health care.
Is the presence of Metabolic Syndrome associated with an increased odds of chronic kidney disease in individuals with hypertension and/or diabetes mellitus?
Cross-Sectional (n=788)
Is the presence of Metabolic Syndrome associated with an increased odds of chronic kidney disease in individuals with hypertension and/or diabetes mellitus?
Odds Ratio: 2.07 (95% CI 1.25–3.44)
Metabolic syndrome and its components are independently associated with a significantly increased risk of chronic kidney disease in primary care patients with hypertension and/or diabetes.
May inform CKD risk stratification in hypertension/diabetes; leaves open causality and need for prospective trials.
PURPOSE: To identify the associations between MetS and its components and chronic kidney disease (CKD) in a population with arterial hypertension (AH), or diabetes mellitus (DM) accompanied by the Primary Health Care (PHC). PATIENTS AND METHODS: A cross-sectional study with 788 individuals diagnosed with AH and/or DM followed by PHC of Viçosa, Brazil. Anthropometric, biochemical and clinical measures were performed for the diagnosis of MetS and CKD. MetS was identified using the NCEP-ATPIII criteria. CKD was identified by estimating the glomerular filtration rate using the CKD-EPI equation. Logistic regression models were used to estimate the chances of CKD associated with MetS and its components and specific combinations of components. RESULTS: The prevalence of MetS reported in the population was 65.4%, that of hidden CKD was 15.4%. The prevalence of CKD among participants with MetS was 75.2%. The most prevalent component of MetS in the population was AH (96.7%). Elevated fasting blood glucose, central obesity, and reduced HDL-c were significantly associated with an increased chance of CKD (OR = 2.80, 95% CI 1.76-4.45, OR = 1.68, 95% CI, 05-2.71, OR = 1.61, CI 95% 1.03-2.50, respectively). For the multivariate adjustment, the participants with MetS were 2 times more likely to have CKD than those without MetS (OR = 2.07; 95% CI, 1.25-3.44). The combination of three components of MetS high blood pressure, abdominal obesity and elevated fasting blood glucose and the combination of four components of MetS high blood pressure, reduced HDL-c, high fasting blood glucose and abdominal obesity were associated with increased odds of CKD (OR = 2.67, CI 95% 1.70-4.20, OR = 2.50, CI 95% 1.55-4.02, respectively). CONCLUSION: MetS, as well as its individual or combined components were independently associated with CKD in the population with AH and/or DM accompanied by PHC.
No takes yet. Share an insight, caveat, or question.
Comini et al. (2020) conducted a cross-sectional in Arterial hypertension and/or diabetes mellitus (n=788). Metabolic Syndrome (MetS) vs. Without Metabolic Syndrome was evaluated on Chronic kidney disease (CKD) (OR 2.07, 95% CI 1.25-3.44). Metabolic syndrome was associated with increased odds of chronic kidney disease in individuals with hypertension and/or diabetes (OR 2.07; 95% CI 1.25-3.44).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: